Expansion of cord blood bank storage capacity

「First, to strengthen its domestic business foundation, the company aims eventually to store 20,000 specimens annually, approximately 2.5 times the current level and equivalent to approximately 3% of domestic births.」

「The new “HOPECELL” storage plan, introduced in November 2024, collects and stores both cord blood and umbilical cord tissue, enabling more reliable storage of valuable cells available only at childbirth. The plan is steadily gaining market traction. As a result, average revenue per customer increased compared with the previous plan, while the number of new umbilical cord storage contracts rose sharply to approximately 2.1 times the year-earlier level.」

「StemCell Institute | Cell processing and storage center | Land, buildings, cell processing equipment and cell storage equipment | ¥1.1 billion | Internal funds, borrowings and equity financing | February 2025 | March 2027 | Increase in cell processing and storage capacity, etc.」

「Toward its medium-term management target of 20,000 specimens, equivalent to a storage rate of approximately 3% of domestic births, the company focused on educational activities such as study sessions for the media, in addition to real-world marketing, including presentations and public relations activities at medical institutions, and digital marketing, including online advertising and social media.」

「StemCell Institute | Cell Storage Center | Cell storage equipment | ¥398 million | Internal funds | August 2024 | March 2031 | Cell storage capacity: approximately 96,000 specimens」

「The company recorded a record-high number of stored specimens and is progressing steadily toward its medium-term target of a storage rate of 3% of births, which is expected to generate revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion when achieved.」

「The company is steadily strengthening operations, including adding administrative offices, at the Yokohama Cell Processing Center and Second Storage Center, which began operations in 2021 and can handle three times the previous scale, in preparation for future growth in the number of specimens and further business expansion.」

「StemCell Institute | Cell Storage Center | Cell storage equipment | Planned investment: ¥154 million | Scheduled completion: March 2024 | Cell storage capacity: approximately 64,000 specimens」

「The company has already secured processing capacity for approximately 20,000 specimens annually, its medium-term target and approximately three times the previous capacity.」

「In preparation for growth in the number of specimens in the post-COVID-19 era, the company is strengthening the operating structure of the Yokohama Cell Processing Center and Second Storage Center, which began operations last year at three times the previous scale, to prepare for further business growth.」

「To prepare for future growth in the number of specimens, the company is strengthening operations at the Yokohama Cell Processing Center and Second Storage Center, which began operations last year and can handle three times the previous scale, thereby preparing for further business growth.」

「StemCell Institute operates a cell banking business for cells derived from perinatal tissues such as cord blood and umbilical cords for regenerative medicine and cell therapy. It is also developing new treatments and regenerative medicine products using these cells, as well as expanding its business through development and investment in regenerative medicine, fertility treatment, childbirth and child-rearing, based on these business foundations.」

「The company has already established a cell processing center capable of handling three times its current scale. By strengthening marketing activities and promoting regenerative medicine using cells such as cord blood, it aims to increase stored specimens, improve its gross profit margin, and raise its operating margin to the near-term target of 25% over approximately 3 years.」

「As of the end of March 2021, the company stored 58,069 of the 58,796 samples stored in Japan, according to the Ministry of Health, Labour and Welfare's Health Insurance Bureau report, "Report on Cord Blood Transfer Results, etc." This represents a 98.8% share, making it Japan's largest private cord blood bank.」

「In December 2020, the company invested, together with major pharmaceutical companies and others, in Cuorips Inc. (headquartered in Chuo-ku, Tokyo), a regenerative medicine venture originating from Osaka University that aims to obtain regulatory approval for iPS cell-derived cardiac muscle sheets. Digital marketing has been steadily producing results, and as of January, the number of requests for information, a leading KPI, was running well above its previous record high.」

「The newly prioritized web marketing initiatives have been launched successfully, and the monthly number of new storage customers has recovered to pre-COVID-19 levels.」

「As of the end of December last year, the number of storage customers exceeded 52,000, giving the company an approximately 99% share of the domestic market. While strengthening its business infrastructure, the company is also pursuing joint research with organizations including the Institute of Medical Science Hospital of the University of Tokyo to expand its business.」

「The cumulative number of storage customers has exceeded 50,000, and the number of monthly contracted specimens continues to grow. The cord blood storage rate in Japan remains low at approximately 0.6% of births, compared with 3–5% in the United States and 12% in South Korea. The company is developing the infrastructure required to meet further growth in demand.」

「StemCell Institute, which operates Japan's largest private cord blood bank, saw the number of stored specimens in the first quarter increase 66.0% year on year and perform strongly. Monthly contracted specimens continue to reach new highs, and demand for cord blood storage is expected to increase significantly further as these clinical studies progress. The company is also focusing on securing personnel while expanding its business infrastructure for collection and storage.」

「StemCell Institute, which operates Japan's largest cord blood bank in the advanced medical treatment field, with approximately 99% of the share of new storage customers, continued to see strong growth in new storage, with revenue up 31.3% year on year and operating profit up 93.4%.」

「The foundation has steadily expanded, including the recording of monthly highs in new contracts twice during the first half, and we believe the business has entered a full-fledged growth trajectory.」

「As of the end of June, the number of storage customers was 44,028.」

「The number of storage customers was 43,207 as of the end of March.」

「As of the end of September this year, the number of storage customers was 41,889.」

「As of the end of June this year, the number of storage customers had risen to 41,128, continuing its steady growth.」

「StemCell Institute, which holds approximately 95% of the domestic market, saw the number of new storage customers grow steadily, rising approximately 7% year on year. As of the end of March this year, the number of storage customers was 40,382.」

「At StemCell Institute, the number of new customers storing samples in the third quarter increased steadily to approximately 115% of the year-earlier level. As Japan’s national policy strongly promotes the practical application of regenerative medicine, the company expects the number of stored samples, with the domestic storage rate still at approximately 0.3%, to increase significantly as clinical trials raise awareness of cord blood banking.」

「StemCell Institute, which holds more than 90% of the domestic market, is primarily engaged in the long-term storage of cord blood-derived stem cells in preparation for future diseases and regenerative and cell therapies. As of the end of June this year, the number of stored samples had steadily increased to 38,016.」

「As of the end of March this year, the number of stored samples had steadily increased to 37,215. Against a backdrop of rising expectations for the treatment of intractable diseases through regenerative medicine, the company views the market’s future potential as very high and will continue to focus on communicating the value of storage and expanding the number of stored samples.」